We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Cangene Announces Extension of VIGIV Biodefence Contract with U.S. Government

News   Sep 27, 2013

 
Cangene Announces Extension of VIGIV Biodefence Contract with U.S. Government
 
 
 

RELATED ARTICLES

Sprouty 1 and Sprouty 2 Offer Potential to Combat Cancer

News

Two molecules, Sprouty 1 and Sprouty 2, modify the survival of effector T cells and the development of memory CD8 T cells. These findings offer promising potential for immunotherapeutic strategies to combat cancer and chronic infections.

READ MORE

A Cup of Strawberries a Day Keeps the Doctor Away

News

Less than a cup of strawberries a day could mitigate colonic inflammation for IBD sufferers and improve gut health.

READ MORE

Brain Cancer Potentially Resists Immunotherapies by Trapping T Cells in Bone Marrow

News

Certain brain cancers are associated with low numbers of immune system T-cells circulating in the peripheral blood. Low T-cell numbers can be a side-effect of cancer treatment. But it now appears that there is more to the story of these missing T-cells.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE